Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation

Kelley Keefe, Meysam Kebriaei, Andrew Gard, Arun Angelo Patil

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The use of thrombolytics delivered through an external ventricular drain has improved outcomes in intraventricular hemorrhage, a disease with a poor prognosis; however, presence of an arteriovenous malformation is generally considered a contraindication to thrombolytic use. Due do the high mortality with the current standard of care, thrombolytics should be considered as an acceptable treatment option despite the presence of an arteriovenous malformation in certain clinical situations. We review the available literature and present an additional patient to make the case for the use of thrombolytics for intraventricular hemorrhage from an arteriovenous malformation.

Original languageEnglish (US)
Pages (from-to)526-529
Number of pages4
JournalJournal of Clinical Neuroscience
Volume21
Issue number3
DOIs
StatePublished - Mar 1 2014

Fingerprint

Arteriovenous Malformations
Tissue Plasminogen Activator
Hemorrhage
Standard of Care
Mortality
Therapeutics

Keywords

  • Intracranial arteriovenous malformation
  • Intracranial hemorrhage
  • Intraventricular injections
  • Thrombolytic therapy

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation. / Keefe, Kelley; Kebriaei, Meysam; Gard, Andrew; Patil, Arun Angelo.

In: Journal of Clinical Neuroscience, Vol. 21, No. 3, 01.03.2014, p. 526-529.

Research output: Contribution to journalArticle

Keefe, Kelley ; Kebriaei, Meysam ; Gard, Andrew ; Patil, Arun Angelo. / Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation. In: Journal of Clinical Neuroscience. 2014 ; Vol. 21, No. 3. pp. 526-529.
@article{ff4ec9c6fdb34bfea508868ed8a540cb,
title = "Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation",
abstract = "The use of thrombolytics delivered through an external ventricular drain has improved outcomes in intraventricular hemorrhage, a disease with a poor prognosis; however, presence of an arteriovenous malformation is generally considered a contraindication to thrombolytic use. Due do the high mortality with the current standard of care, thrombolytics should be considered as an acceptable treatment option despite the presence of an arteriovenous malformation in certain clinical situations. We review the available literature and present an additional patient to make the case for the use of thrombolytics for intraventricular hemorrhage from an arteriovenous malformation.",
keywords = "Intracranial arteriovenous malformation, Intracranial hemorrhage, Intraventricular injections, Thrombolytic therapy",
author = "Kelley Keefe and Meysam Kebriaei and Andrew Gard and Patil, {Arun Angelo}",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.jocn.2013.04.031",
language = "English (US)",
volume = "21",
pages = "526--529",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation

AU - Keefe, Kelley

AU - Kebriaei, Meysam

AU - Gard, Andrew

AU - Patil, Arun Angelo

PY - 2014/3/1

Y1 - 2014/3/1

N2 - The use of thrombolytics delivered through an external ventricular drain has improved outcomes in intraventricular hemorrhage, a disease with a poor prognosis; however, presence of an arteriovenous malformation is generally considered a contraindication to thrombolytic use. Due do the high mortality with the current standard of care, thrombolytics should be considered as an acceptable treatment option despite the presence of an arteriovenous malformation in certain clinical situations. We review the available literature and present an additional patient to make the case for the use of thrombolytics for intraventricular hemorrhage from an arteriovenous malformation.

AB - The use of thrombolytics delivered through an external ventricular drain has improved outcomes in intraventricular hemorrhage, a disease with a poor prognosis; however, presence of an arteriovenous malformation is generally considered a contraindication to thrombolytic use. Due do the high mortality with the current standard of care, thrombolytics should be considered as an acceptable treatment option despite the presence of an arteriovenous malformation in certain clinical situations. We review the available literature and present an additional patient to make the case for the use of thrombolytics for intraventricular hemorrhage from an arteriovenous malformation.

KW - Intracranial arteriovenous malformation

KW - Intracranial hemorrhage

KW - Intraventricular injections

KW - Thrombolytic therapy

UR - http://www.scopus.com/inward/record.url?scp=84895098299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895098299&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2013.04.031

DO - 10.1016/j.jocn.2013.04.031

M3 - Article

C2 - 24134809

AN - SCOPUS:84895098299

VL - 21

SP - 526

EP - 529

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 3

ER -